VIIV-CNA106030

Study Sponsor: ViiV

Study Title

A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity

Medicine or Vaccine (generic name)

abacavir

Sponsor Identification Number

CNA106030

Trial Registry Identification Number(#'s)

NCT00340080

Medical Condition

Infection, Human Immunodeficiency Virus

Phase

Phase 4

Link to study details on the ViiV Clinical Study Register

http://www.viiv-clinicalstudyregister.com/study/CNA106030

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00340080

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study was sponsored by GlaxoSmithKline, prior to the establishment of ViiV Healthcare in 2009. Following the establishment of ViiV Healthcare, GlaxoSmithKline transferred its work in the field of HIV to ViiV Healthcare

Date Added to this Site

January 2014